سوق منظمة تطوير وتصنيع العقود العالمية للمواد البيولوجية (CDMO) – اتجاهات الصناعة والتوقعات حتى عام 2031

تحليل حجم سوق منظمة تطوير وتصنيع العقود البيولوجية (CDMO)  

وقد ساعدت عوامل مثل زيادة حالات جراحات دمج العمود الفقري إلى جانب ارتفاع عدد السكان المسنين في جميع أنحاء العالم، في دفع نمو السوق. ومن المتوقع أن يؤدي ارتفاع الإنفاق على الرعاية الصحية والتطورات في الابتكار لإطلاق منتجات جديدة إلى زيادة نمو السوق.

تحلل شركة Data Bridge Market Research أن سوق منظمة تطوير وتصنيع عقود المستحضرات البيولوجية العالمية (CDMO) الذي بلغ 14,971.57 مليون دولار أمريكي في عام 2023، سيصل إلى 34,378.10 مليون دولار أمريكي بحلول عام 2031، ومن المتوقع أن يخضع لمعدل نمو سنوي مركب بنسبة 11.0٪ خلال الفترة المتوقعة. ومن المتوقع أن تهيمن "شركات التكنولوجيا الحيوية" في قطاع المستخدمين النهائيين على السوق بسبب البحث والتطوير البيولوجي الأعلى من قبل هذه الشركات. بالإضافة إلى الرؤى حول سيناريوهات السوق مثل القيمة السوقية ومعدل النمو والتجزئة والتغطية الجغرافية واللاعبين الرئيسيين، تتضمن تقارير السوق التي أعدتها شركة Data Bridge Market Research أيضًا تحليل الخبراء المتعمق وعلم الأوبئة للمرضى وتحليل خطوط الأنابيب وتحليل الأسعار والإطار التنظيمي.

نطاق التقرير وتقسيم السوق

Market Definition

A Biologics CDMO (Contract Development and Manufacturing Organization) is a specialized company that offers services for the development, manufacturing, and testing of biopharmaceutical products. Biologics, which include complex drugs derived from living cells or organisms, are a key focus. These organizations assist biopharmaceutical companies in various stages of drug development by providing expertise in process development, analytical testing, and regulatory compliance.

Global Biologics Contract Development and Manufacturing Organization (CDMO) Market Dynamics

Drivers

• Increasing Demand for Biologics

The pharmaceutical industry is experiencing a surge in demand for biologics due to their efficacy in treating complex diseases. Biologics CDMOs are essential in meeting this demand, offering specialized expertise in the intricate production processes required for these advanced therapeutic products. As biologics become a cornerstone of modern medicine, the collaborative efforts between pharmaceutical companies and biologics CDMOs contribute to addressing patient needs and expanding treatment options.

• Cost-Efficiency and Flexibility

Biologics CDMOs provide a cost-effective solution for drug developers by offering access to established facilities, equipment, and skilled personnel. Outsourcing to these organizations allows companies to avoid substantial upfront capital investments, reducing overall development costs. Additionally, the flexibility offered by Biologics CDMOs enables companies to adapt production capacities quickly, responding to market fluctuations and ensuring efficient resource utilization in the rapidly evolving biopharmaceutical landscape.

Opportunities

• Advanced Therapies and Personalized Medicine

With the rise of gene and cell therapies, CDMOs specializing in these advanced therapies stand to benefit. These therapies often require highly specialized manufacturing processes, and CDMOs that can navigate the complexities of production, quality control, and scalability may capture a growing market share.

• Digitalization of the industry

The integration of digital technologies, artificial intelligence, and automation into biologics manufacturing is becoming crucial. CDMOs embracing Industry 4.0 concepts can enhance efficiency, reduce costs, and ensure the quality of biologic products. The implementation of data analytics in real-time monitoring and decision-making processes may position CDMOs as leaders in the evolving landscape of smart manufacturing for biologics.

Restraints/Challenges

• Complex Manufacturing Processes

The intricate nature of biologics manufacturing, involving living cells and sophisticated purification steps, presents challenges in maintaining consistency and reproducibility. Variability in cell cultures, purification yields, and other factors can impact product quality, requiring advanced process control and monitoring to ensure robust production.

• Regulatory Hurdles

Strict regulatory oversight is inherent in the biologics industry due to the complexity and sensitivity of these therapeutic products. Navigating diverse global regulatory landscapes, staying abreast of evolving guidelines, and ensuring compliance with quality standards demand substantial investments in documentation, validation, and adherence to good manufacturing practices (GMP). Any regulatory missteps can result in delays and increased costs, underscoring the importance of meticulous regulatory strategies for CDMOs.

This biologics contract development and manufacturing organization (CDMO) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the biologics contract development and manufacturing organization (CDMO) Market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Biologics Contract Development and Manufacturing Organization (CDMO) Market Scope

The biologics contract development and manufacturing organization (CDMO) market is segmented based on the basis of surgery, product, and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

• Gene products
• Vaccines
• Stem Cells
• Monoclonal Antibodies
• Others

Service Type

• Manufacturing
• Research and Development
• Clinical Trials
• Others

End-Users

• Biotechnology Companies
• Biopharmaceutical Companies
• Others

Global Biologics Contract Development and Manufacturing Organization (CDMO) Market Regional Analysis/Insights

The biologics contract development and manufacturing organization (CDMO) Market is analyzed and market size insights and trends are provided by d by country, product, type, service type, and end-users as referenced above.

The countries covered in the market report are U.S., Canada, Mexico, Germany, France, U.K., Belgium, Lithuania, Austria, Ireland, Norway, Poland, Italy, Spain, Russia, Turkey, Netherlands Switzerland, rest of Europe, Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, rest of Asia-Pacific, Brazil, Argentina, rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel and rest of Middle East and Africa.

North America is expected to dominate the market due to higher production rates of biological drugs.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period due to the rising research and development activities of pharmaceutical and biotechnological companies.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

The biologics contract development and manufacturing organization (CDMO) market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for biologics contract development and manufacturing organization (CDMO) market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the biologics contract development and manufacturing organization (CDMO) market. The data is available for historic period 2010-2020.

Competitive Landscape and Biologics Contract Development and Manufacturing Organization (CDMO) Market Share Analysis

يوفر المشهد التنافسي لسوق منظمة تطوير وتصنيع العقود البيولوجية (CDMO) تفاصيل حسب المنافس. تتضمن التفاصيل نظرة عامة على الشركة، والمالية، والإيرادات المتولدة، وإمكانات السوق، والاستثمار في البحث والتطوير، ومبادرات السوق الجديدة، والحضور العالمي، ومواقع الإنتاج والمرافق، والقدرات الإنتاجية، ونقاط القوة والضعف في الشركة، وإطلاق المنتج، وعرض المنتج ونطاقه، وهيمنة التطبيق. ترتبط نقاط البيانات المذكورة أعلاه فقط بتركيز الشركات فيما يتعلق بسوق منظمة تطوير وتصنيع العقود البيولوجية (CDMO).

بعض اللاعبين الرئيسيين العاملين في سوق منظمة تطوير وتصنيع عقود المواد البيولوجية (CDMO) هم:

• مجموعة بوهرينغر إنجلهايم (ألمانيا)
• ووشي بيولوجيكس (الصين)
• سامسونج بيولوجيكس (كوريا الجنوبية)
• مجموعة لونزا (سويسرا)
• فوجي فيلم ديوسينث للتكنولوجيا الحيوية الولايات المتحدة الأمريكية المحدودة (الولايات المتحدة)
• شركة تويوبو المحدودة (اليابان)
• شركة باركسيل الدولية (الولايات المتحدة)
• أيقونة PLC (أيرلندا)
• شركة باينيكس المحدودة (كوريا الجنوبية)
• جيه ار اس فارما (ألمانيا)
• رينتشلر للتكنولوجيات الحيوية (ألمانيا)
• AGC Biologics (الولايات المتحدة)
• شركة كاتالنت (الولايات المتحدة)

SKU-70530